Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

For more information regarding Bristol-Myers Squibb Clinical Trial participation, pleasevisit www.BMSStudyConnect.com Inclusion Criteria:

• Must have active ulcerative colitis (UC) extending ≥ 15 cm from the anal verge andconfirmed by a screening/baseline colonoscopy/sigmoidoscopy prior to the randomizationvisit
• Must have documented diagnosis of UC of at least 3 months' duration prior to screening
• Must have active moderate to severe UC, as defined by a modified Mayo score of 5 to 9points, inclusive, which includes a stool frequency (SF) subscore of ≥ 2, and a rectalbleeding (RB) subscore ≥ 1, and a screening endoscopic (ES) subscore of ≥ 2

Exclusion Criteria:

• Previous/current documented diagnosis of CD, indeterminate colitis, ischemic colitis,or pseudomembranous colitis (other than associated with Clostridium difficile [C.difficile])
• Stool positive for C. difficile toxin at screening visit
• Current or recent (within 12 weeks prior to the randomization visit) evidence offulminant colitis, abdominal abscess, toxic megacolon, or bowel perforation Other protocol-defined inclusion/exclusion criteria apply